In today’s drug development climate, we’re encouraged to “think global, act local.” I have had the privilege of supporting the development of important new therapies for clients around the globe. But sometimes, it is helpful to take a step back and look at the exciting science going on in your own backyard. With that spirit […]Read More
Author: Mark Reimer
Dr. Reimer leads a highly skilled team of clinical pharmacologists, pharmacometricians, biostatisticians, and medical writers who are committed to providing high-quality, regulatory-compliant PK/PD analysis and reporting services for the pharma/biotech industry. He is an experienced leader in the development of new drug therapies with over twenty-five years of progressive scientific, managerial and executive responsibilities in the field of drug research, including ADME/T and bioanalysis. His experience includes the design, execution and interpretation of a wide variety of preclinical services used in the pharmaceutical and biotechnology industries to bring new molecular entities through the drug development process. He led preclinical research efforts at Theratechnologies, a major Canadian biopharmaceutical company, and was responsible for the inception, build-out, and consistent profitability of the drug metabolism unit at MDS Pharma Services, at the time one of the world’s top-five contract research organizations. Dr. Reimer earned a PhD in chemistry at the University of Manitoba and completed a post-doctoral fellowship at the College of Pharmacy of the University of Arizona.